XML 146 R3.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current Assets    
Cash and cash equivalents $ 22,593 $ 32,154
Marketable securities 27,942 37,072
Prepaid and other current assets 3,389 2,650
Total current assets 53,924 71,876
Property and equipment, net 175 296
Acquired license-intangible, net 263 334
Other assets 332 528
Total assets 54,694 73,034
Liabilities    
Accounts payable 2,421 2,655
Accrued liabilities 4,169 3,728
Total current liabilities 6,590 6,383
Other long-term liabilities 210 327
Total liabilities 6,800 6,710
Commitments and Contingencies (Note 14)
Stockholders' Equity    
Common stock, $0.001 par value, authorized 33,333,333 shares; issued 8,150,635 and 7,866,799 shares, at December 31, 2023 and December 31, 2022, respectively; and outstanding, 8,149,897 and 7,866,061 shares, at December 31, 2023 and December 31, 2022, respectively 8 8
Additional paid-in capital 576,971 574,548
Treasury stock, at cost; 738 shares at December 31, 2023 and December 31, 2022 respectively (708) (708)
Accumulated deficit (528,081) (507,241)
Accumulated other comprehensive loss (42) (29)
Total Lisata Therapeutics, Inc. stockholders' equity 48,148 66,578
Non-controlling interests (254) (254)
Total equity 47,894 66,324
Total liabilities, non-controlling interests and stockholders' equity $ 54,694 $ 73,034